Loading...
Treatment options for patients with relapsed chronic lymphocytic leukemia (CLL) are often limited by patient age or performance status, prior therapies, or failure to respond to available agents and regimens. Investigators tested a novel approach using the cyclin-dependent kinase inhibitor flavopiridol in a single-arm phase II study of 64 heavily pretreated patients with CLL (median age, 60). Most patients exhibited bulky adenopathy (73%) and high-risk genetic features (deletion 17p13.1, 33%; deletion 11q22.3, 44%; complex karyotypes, 42%). All patients received prior nucleoside analogue treatment. Because of excessive toxicity with the initially tested flavopiridol dose and schedule, about half of enrolled patients received a modified trea…